Fenofibrate-13C6非诺贝特-13C6,1261

Fenofibrate-13C6 产品活性：Fenofibrate-13C6是氘代标记的Fenofibrate。Fenofibrate 是一种选择性的 PPARα 激动剂，EC50 为 30 μM。Fenofibrate 抑制细胞色素 P450 亚型, 对 CYP2C19，CYP2B6，CYP2C9，CYP2C8 和 CYP3A4 的 IC50 分别为 0.2，0.7，9.7，4.8 和 142.1 μM。 产品来源： www.medchemexpress.cn/fenofibrate-13c6.html 研究领域：Others | Metabolic Enzyme/Protease | Vitamin D Related/Nuclear Receptor | Cell Cycle/DNA Damage | Autophagy 作用靶点：Isotope-Labeled Compounds | Cytochrome P450 | PPAR | Autophagy In Vitro: Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.Fenofibrate is a relatively potent inhibitor of CYP2B6 (IC50=0.7±0.2 μM) and CYP2C19 (IC50=0.2±0.1 μM). Fenofibrate is also a moderate inhibitor of CYP2C8 (IC50=4.8±1.7 μM) and CYP2C9 (IC50=9.7 μM). Fenofibrate binds to and inhibits cytochrome P450 epoxygenase (CYP)2C with higher affinity than to PPARα. Fenofibrate is a well-known PPARα agonist, but an in vitro assessment of 209 frequently prescribed drugs and related xenobiotics suggests that Fenofibrate is also a potent inhibitor of cytochrome P450 epoxygenase (CYP)2C. The affinity of Fenofibrate to CYP2C is >10 times higher (EC50=2.39±0.4 μM) than to PPARα (EC50=30 μM). Fenofibrate at a low dose inhibits CYP2C8 activity without PPARα activation. In Vivo: Daily intake of Fenofibrate at this low dose (10 μg/g/day) inhibits retinal and choroidal neovascularization induced by CYP2C8 overexpression by 29% (P=0.021) and 36% (P=1.2×10?9) respectively. 相关产品：Retinoic acid | Rosiglitazone | GW9662 | Verapamil | Pioglitazone | GW6471 | Fenofibrate | Apigenin | Fisetin | Pirinixic acid | Chlorpromazine | T0070907 | 5-Aminosalicylic Acid | Letrozole | Abiraterone | Ketoconazole | 1-Aminobenzotriazole | Troglitazone | Itraconazole | Quinidine (15% dihydroquinidine) | Daidzein | Cepharanthine | Clarithromycin | Astaxanthin | GW 501516 | Icariin | Atovaquone 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。